DRMA - Dermata Therapeutics, Inc.
IEX Last Trade
1.37
0.040 2.920%
Share volume: 0
Last Updated: Thu 26 Dec 2024 03:28:03 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
3.82%
PREVIOUS CLOSE
CHG
CHG%
$1.33
0.04
3.01%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
24.07%
1 Month
16.52%
3 Months
-13.55%
6 Months
-50.74%
1 Year
115.85%
2 Year
636.67%
Key data
Stock price
$1.37
DAY RANGE
N/A - N/A
52 WEEK RANGE
$0.62 - $13.35
52 WEEK CHANGE
-$84.60
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Gerry Proehl
Region: US
Website: dermatarx.com
Employees: 8
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: dermatarx.com
Employees: 8
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company was incorporated in 2014 and is headquartered in San Diego, California.
Recent news